Genetic alterations in FAT1, YAP1 or WWTR1 genes are commonly seen in head and neck squamous cell carcinoma (HNSCC) patients. Targeting Hippo and MAPK pathways in combination has proven effective in preclinical models of HNSCC.
Poseida Therapeutics Inc. has updated progress made in its early-stage pipeline of differentiated T stem cell memory cell-rich allogeneic CAR T therapies in oncology and autoimmune diseases.
At the recent SITC meeting in Houston, Teva Pharmaceutical Industries Ltd. reported preclinical data for the fusion protein TEV-56278, which is in phase I development.
Many studies have linked the presence of specific bacteria to various diseases. But a general overgrowth of gut bacteria can be a symptom of different conditions, including colorectal cancer and inflammatory bowel disease. A study counting gut microbiome proposes that microbial load, rather than the disease, could explain the presence of certain pathogens.
Gandeeva Therapeutics Inc. has divulged serine/threonine-protein kinase B-raf (BRAF)/MAP2K1 (MEK1) interaction stabilizers reported to be useful for the treatment of brain metastasis.
MD Biopharm Co. Ltd. has identified compounds acting as mitogen-activated protein kinase kinase kinase 11 (MAP3K11; MLK3) and kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer, viral infection, Parkinson’s disease, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH) and tuberculosis.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has synthesized compounds acting as tyrosine-protein kinase receptor UFO (AXL) inhibitors reported to be useful for the treatment of cancer.
ENPP1 contributes to establishing an immunosuppressive tumor microenvironment by blocking the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling, which is critical in antitumor immunity. The inhibition of ENPP1 is an emerging strategy under exploration for cancer immunotherapy.
RSS
